# A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Study · id `cardio:ct-nct06221969` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06221969](<https://clinicaltrials.gov/study/NCT06221969>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06221969

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1024 participants.

## Technical summary

Registry record NCT06221969. Randomized; no masking; primary purpose treatment. Start 2024-01-16 (actual); primary completion 2026-03-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1024 participants (enrolled count; ClinicalTrials.gov record NCT06221969, source copy `cardio:ctgov-nct06221969-2026-10-19`, retrieved 2026-10-26)
- Started: 2024-01-16 (actual) (ClinicalTrials.gov record NCT06221969, source copy `cardio:ctgov-nct06221969-2026-10-19`, retrieved 2026-10-26)
- Primary completion: 2026-03-04 (actual) (ClinicalTrials.gov record NCT06221969, source copy `cardio:ctgov-nct06221969-2026-10-19`, retrieved 2026-10-26)
- Completion: 2026-04-06 (actual) (ClinicalTrials.gov record NCT06221969, source copy `cardio:ctgov-nct06221969-2026-10-19`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Canada; Colombia; India; South Africa; Taiwan (ClinicalTrials.gov record NCT06221969, source copy `cardio:ctgov-nct06221969-2026-10-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06221969-2026-10-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
- Condition: Type 2 Diabetes
- Intervention (Drug): Cagrilintide
- Intervention (Drug): Semaglutide
- Intervention (Drug): Tirzepatide
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry intervention name matches this record: Tirzepatide (`cardio:tirzepatide`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 25738cea7a2c2d76c10bc4c66628e31424873e406c64243a63286e0c72d81ed5
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
